An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed b
Administered By
Awarded By
Contributors
- Rabinovich, Consuelo Egla Diana Principal Investigator
Start/End
- October 16, 2017 - June 30, 2020